Targeted drug offers 'landmark moment' in advanced breast cancer treatment 

A phase 3 clinical trial of capivasertib alongside hormone therapy suggests the combination could become the new treatment for patients with advanced forms of the most common type of breast cancer.

A "landmark moment" in the treatment of advanced breast cancer could benefit thousands of women each year, scientists have said.

A new targeted drug has shown "fantastic" results — shrinking tumours and doubling the amount of time people have before their disease progresses.